Hydrogen Therapy Prevents Brain Cancer Recurrence in New Study
- Authors
- Ruotian Zhang, Yanzhen Song, Jiawei Yao, Hanfeng Qin, Yicheng Ye, Junbin Gao, Cheng Zhang, Dayong Han, Ming Gao, Hao Chen, Chen Xin, Shiguang Zhao, Kun Liu, Yingfeng Tu, Zhili Xu
- Journal
- Small
- Year
- 2025
- DOI
- 10.1002/smll.202408809
- Study Type
- Rat
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- China
- Health Condition
- Glioblastoma
- Body System
- Nervous System
TL;DR
Scientists have developed a new treatment method using tiny magnesium-powered motors that deliver cancer drugs directly to the brain tumor site, enhancing drug effectiveness and reducing tumor recurrence.
Key Finding
In rats, hydrogen gas produced by magnesium micromotors combined with chemotherapy reduced glioblastoma recurrence more effectively than chemotherapy alone by decreasing inflammation and improving drug penetration into tumors.
Summary
Researchers developed a tiny robot-like device made of magnesium that produces hydrogen gas and delivers a chemotherapy drug directly into the brain tumor cavity after surgery. In rat studies, the hydrogen gas reduced inflammation and helped the chemotherapy drug penetrate the tumor more effectively, while also changing the tumor's immune environment to make it more responsive to treatment. This combination approach significantly reduced tumor regrowth in the animal model.
Practical Takeaway
While this study shows promising results in rats, it is a preclinical animal study and has not been tested in humans. The approach is highly specialized (using implanted micromotors in the brain) and represents early-stage research. Much more work would be needed before this could potentially become a clinical treatment option.
Abstract
Postoperative recurrence of glioblastoma (GBM) is a key contributing factor to the unfavorable prognosis of patients. Chemotherapy has been extensively employed as a postoperative treatment for GBM; however, the produced drug resistance significantly undermines the chemotherapeutic efficacy. Herein, a multifunctional system based on magnesium micromotor (Mg-Motor-DOX) is designed and fabricated that can generate hydrogen gas in situ and actively deliver the chemotherapeutic drug doxorubicin (DOX). Utilizing a temperature-sensitive hydrogel, Mg-Motor-DOX is administrated in situ to the residual cavity of the tumor after subtotal GBM resection. The produced H2 by the Mg-water reaction not only propels the motion of motors but also functions as an antioxidant to effectively alleviate the neuroinflammation caused by GBM resection. The H2 bubbles create a pronounced vortex flow in situ, greatly enhancing the DOX penetration and the sensitivity of GBM cells to DOX. Therefore, synergistic hydrogen-chemotherapy significantly inhibits the recurrence of the in situ GBM model. RNA-Seq technology further elucidates the role of the strategy in modulating the tumor immune microenvironment via converting cold tumors into hot tumors, thereby establishing a theoretical foundation for the clinical implementation of synergistic hydrogen-chemotherapy.